Overcoming immunogenicity associated with the use of biopharmaceuticals

References

• Buttel IC, Chamberlain P, Chowers Y et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals39, 100–109 (2011).
   PubMed Web of Science ®Google Scholar
• Wadhwa M, Thorpe R. Unwanted immunogenicity: lessons learned and future challenges. Bioanalysis2, 1073–1084 (2011).
   Google Scholar
• Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med.346, 469–475 (2002).
   PubMed Web of Science ®Google Scholar
• Li J, Yang C, Xia Y et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood98, 3241–3248 (2001).
   PubMed Web of Science ®Google Scholar
• Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods333, 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Kirshner S. Immunogenicity of therapeutic proteins: a regulatory perspective. In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG (Ed.). John Wiley and Sons Inc., NY, USA (2011).
   Google Scholar
• Shankar G, Pendley C, Stein KE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol.25, 555–561 (2007).
   PubMed Web of Science ®Google Scholar
• Schneider CK, Papaluca M, Kurki P. A European perspective on immunogenicity evaluation. Nat. Biotechnol.27, 507–508 (2009).
   PubMed Web of Science ®Google Scholar
• Ragnhammar P, Friesen HJ, Frodin JE et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood84, 4078–4087 (1994).
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med.358, 1109–1117 (2008).
   PubMed Web of Science ®Google Scholar
• Berger C, Neiesner U. Immunogenicity of microbial enzymes for oral replacement therapy in pancreatic exocrine insufficiency. In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG (Ed.). John Wiley & Sons, NY, USA (2011).
   Google Scholar
• Ponce R, Abad L, Amaravadi L et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol.54, 164–182 (2009).
   PubMed Web of Science ®Google Scholar
• Kramer D. Standardization and validation of immunoassays. In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG (Ed.). John Wiley and Sons Inc., NY, USA, 233–242 (2011).
   Google Scholar
• Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal.48, 1267–1281 (2008).
   PubMed Web of Science ®Google Scholar
• Meager A. Measurement of cytokines by bioassays: theory and application. Methods38, 237–252 (2006).
   PubMedGoogle Scholar
• Lallemand C, Meritet JF, Erickson R et al. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J. Interferon Cytokine Res.28, 393–404 (2008).
   PubMedGoogle Scholar
• Lallemand C, Meritet JF, Blanchard B, Lebon P, Tovey MG. One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. J. Immunol. Methods356, 18–28 (2010).
   PubMedGoogle Scholar
• Ottesen JL, Nilsson P, Jami J et al. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia37, 1178–1185 (1994).
   PubMed Web of Science ®Google Scholar
• Miller LL, Korn EL, Stevens DS et al. Abrogation of the hematological and biological activities of the interleukin-3/granulocyte–macrophage colony-stimulating factor fusion protein PIXY321 by neutralizing anti-PIXY321 antibodies in cancer patients receiving high-dose carboplatin. Blood93, 3250–3258 (1999).
   PubMedGoogle Scholar
• Gribben JG, Devereux S, Thomas NS et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet335, 434–437 (1990).
   PubMed Web of Science ®Google Scholar
• Armstrong JK, Hempel G, Koling S et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer110, 103–111 (2007).
   PubMed Web of Science ®Google Scholar
• Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-β (IFN-β) immunogenicity. Clin. Immunol.118, 42–50 (2006).
   PubMed Web of Science ®Google Scholar
• Farrell RA, Giovannoni G. Current and future role of interferon β in the therapy of multiple sclerosis. J. Interferon Cytokine Res.30, 715–726 (2010).
   PubMedGoogle Scholar
• Giovannoni G. Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies. Neurology61(9 Suppl. 5), S13–S17 (2003).
   PubMedGoogle Scholar
• Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J. Clin. Endocrinol. Metab.51, 691–697 (1980).
   PubMed Web of Science ®Google Scholar
• Felipe V, Hawe A, Schellekens H, Jiskoot W. Aggregation and immunogenicity of therapeutic proteins. In: Aggregation of Therapeutic Proteins. Wang W, Roberts C (Eds). John Wiley and Sons Inc., NJ, USA (2010).
   Google Scholar
• Wadhwa M, Skog AL, Bird C et al. Immunogenicity of granulocyte–macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin. Cancer Res.5, 1353–1361 (1999).
   PubMed Web of Science ®Google Scholar
• Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine29, 56–66 (2005).
   PubMedGoogle Scholar
• Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann. Oncol.18, 226–232 (2007).
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Ishii A. Japanese regulatory perspective on immunogenicity In: Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations. Tovey MG (Ed.). John Wiley and Sons Inc., NY, USA (2011).
   Google Scholar
• Hochuli E. Interferon immunogenicity: technical evaluation of interferon-α 2a. J. Interferon Cytokine Res.17(Suppl. 1), S15–S21 (1997).
   Google Scholar
• Davis TA, Maloney DG, Grillo-Lopez AJ et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma with rituximab and interferon-α-2a. Clin Cancer Res.6(7), 2644–2652 (2000).
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol.18, 3135–3143 (2000).
   PubMed Web of Science ®Google Scholar
• Pijpe J, van Imhoff GW, Spijkervet FK et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label Phase II study. Arthritis Rheum.52, 2740–2750 (2005).
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum.41, 1552–1563 (1998).
   PubMed Web of Science ®Google Scholar
• Fakharzadeh SS, Kazazian HH Jr. Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin. Thromb. Hemost.26, 167–171 (2000).
   PubMed Web of Science ®Google Scholar
• Hoffmann S, Cepok S, Grummel V et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-β therapy in multiple sclerosis. Am. J. Hum. Genet.83, 219–227 (2008).
   PubMed Web of Science ®Google Scholar
• Kappos L, Clanet M, Sandberg-Wollheim M et al. Neutralizing antibodies and efficacy of interferon β-1a: a 4-year controlled study. Neurology65, 40–47 (2005).
   PubMed Web of Science ®Google Scholar
• Francis GS, Rice GP, Alsop JC. Interferon β-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology65, 48–55 (2005).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Hurwitz B, Noronha A. Neutralizing antibodies to interferon β-1b are not associated with disease worsening in multiple sclerosis. J. Int. Med. Res.35, 173–187 (2007).
   PubMedGoogle Scholar
• Malucchi S, Sala A, Gilli F et al. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology62, 2031–2037 (2004).
   PubMed Web of Science ®Google Scholar
• Gilli F. Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon β. J. Interferon Cytokine Res.30, 733–741 (2010).
   PubMedGoogle Scholar
• Wee LJ, Simarmata D, Kam YW, Ng LF, Tong JC. SVM-based prediction of linear B-cell epitopes using Bayes feature extraction. BMC Genomics11(Suppl. 4), S21 (2011).
   Google Scholar
• Bryson CJ, Jones TD, Baker MP. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs24, 1–8 (2010).
   PubMed Web of Science ®Google Scholar
• Parker AS, Zheng W, Griswold KE, Bailey-Kellogg C. Optimization algorithms for functional deimmunization of therapeutic proteins. BMC Bioinformatics11, 180 (2010).
   PubMed Web of Science ®Google Scholar
• Cheng PC, Steele CR, Gu L, Song W, Pierce SK. MHC class II antigen processing in B cells: accelerated intracellular targeting of antigens. J. Immunol.162, 7171–7180 (1999).
   PubMedGoogle Scholar
• Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. Antibody response to aggregated human interferon α2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J. Pharm. Sci.95, 1084–1096 (2006).
   PubMedGoogle Scholar
• van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice. Pharm. Res.27, 1812–1824 (2010).
   PubMed Web of Science ®Google Scholar
• Palleroni AV, Aglione A, Labow M et al. Interferon immunogenicity: preclinical evaluation of interferon-α 2a. J. Interferon Cytokine Res.17(Suppl. 1), S23–S27 (1997).
   PubMedGoogle Scholar
• Depil S, Angyalosi G, Morales O et al. Peptide-binding assays and HLA II transgenic Aβ° mice are consistent and complementary tools for identifying HLA II-restricted peptides. Vaccine24, 2225–2229 (2006).
   PubMedGoogle Scholar